256 related articles for article (PubMed ID: 28427506)
1. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.
González Del Alba A; Arranz JÁ; Puente J; Méndez-Vidal MJ; Gallardo E; Grande E; Pérez-Valderrama B; González-Billalabeitia E; Lázaro-Quintela M; Pinto Á; Lainez N; Piulats JM; Esteban E; Maroto Rey JP; García JA; Suárez C
Crit Rev Oncol Hematol; 2017 May; 113():171-190. PubMed ID: 28427506
[TBL] [Abstract][Full Text] [Related]
2. Biennial report on genitourinary cancers.
Fizazi K
Eur J Cancer; 2016 Oct; 66():125-30. PubMed ID: 27569040
[TBL] [Abstract][Full Text] [Related]
3. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
4. New advances in genitourinary cancer: evidence gathered in 2014.
Suárez C; Puente J; Gallardo E; Méndez-Vidal MJ; Climent MA; León L; Olmos D; García del Muro X; González-Billalabeitia E; Grande E; Bellmunt J; Mellado B; Maroto P; González del Alba A
Cancer Metastasis Rev; 2015 Sep; 34(3):443-64. PubMed ID: 26227584
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
6. Evolving Role of Genomics in Genitourinary Neoplasms.
Devitt ME; Dreicer R
Acta Med Acad; 2019 Apr; 48(1):68-77. PubMed ID: 31264434
[TBL] [Abstract][Full Text] [Related]
7. Update in systemic therapy of urologic malignancies.
Mooney D; Paluri R; Mehta A; Goyal J; Sonpavde G
Postgrad Med; 2014 Jan; 126(1):44-54. PubMed ID: 24393751
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib in genitourinary malignancies.
Zhang T; Park SE; Hong C; George DJ
Future Oncol; 2017 Apr; 13(8):755-765. PubMed ID: 27842445
[TBL] [Abstract][Full Text] [Related]
9. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
10. Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Cimadamore A; Scarpelli M; Santoni M; Massari F; Tartari F; Cerqueti R; Lopez-Beltran A; Cheng L; Montironi R
Curr Drug Metab; 2019; 20(4):305-312. PubMed ID: 30799789
[TBL] [Abstract][Full Text] [Related]
11. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
Recine F; Ceresoli GL; Baciarello G; Cerbone L; Calabrò F
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy.
Lattouf JB; Srinivasan R; Pinto PA; Linehan WM; Neckers L
Nat Clin Pract Urol; 2006 Nov; 3(11):590-601. PubMed ID: 17088927
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis and anti-angiogenic therapy in prostate cancer.
Mukherji D; Temraz S; Wehbe D; Shamseddine A
Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
[TBL] [Abstract][Full Text] [Related]
14. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
15. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
[TBL] [Abstract][Full Text] [Related]
16. Advances in urologic oncology "OncoForum": The best of 2019.
Gómez-Veiga F; Alcaraz Asensio A; Burgos Revilla J; Cózar Olmo J
Actas Urol Esp (Engl Ed); 2020 Nov; 44(9):586-596. PubMed ID: 32948345
[TBL] [Abstract][Full Text] [Related]
17. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
Cassinello J; Arranz JÁ; Piulats JM; Sánchez A; Pérez-Valderrama B; Mellado B; Climent MÁ; Olmos D; Carles J; Lázaro M
Clin Transl Oncol; 2018 Jan; 20(1):57-68. PubMed ID: 29134562
[TBL] [Abstract][Full Text] [Related]
18. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
[TBL] [Abstract][Full Text] [Related]
19. Emerging agents for the therapy of advanced prostate cancer.
Hathaway AR; Baker MK; Sonpavde G
Future Oncol; 2015; 11(20):2775-87. PubMed ID: 26367474
[TBL] [Abstract][Full Text] [Related]
20. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]